Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoMed Pharmaceuticals Hires Chief Scientific Officer

Abstract:
NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced today that it has hired Harry C. Ledebur, Jr., PhD. to serve as the company's Vice President Research & Development, Chief Scientific Officer. Prior to joining NanoMed, Dr. Ledebur was Vice President, Operations & Scientific Affairs for Chromos Molecular Systems, Inc. where he was a member of Chromos' Executive Committee and was responsible for all discovery and product development programs along with quality systems, regulatory affairs and site operations.

NanoMed Pharmaceuticals Hires Chief Scientific Officer

Kalamazoo, MI | Posted on June 21st, 2007

"I am extremely pleased to have the opportunity to partner with a
research and development executive of Harry's caliber," said Stephen
Benoit, NanoMed's President and CEO. "His extensive experience in
preclinical discovery research, product and business development within the
biotechnology and pharmaceutical industries should prove to be a tremendous
asset to NanoMed as we build our drug pipeline and forge strategic product
development relationships," Benoit added. NanoMed's lead product is a
nanoparticle formulation of an FDA-approved cancer drug used to treat
adults diagnosed with acute myeloid leukemia. This lead product is expected
to enter human clinical trials in 2008.

"NanoMed is an exciting company with an innovative nanotechnology
platform for the rapid development of a diversified portfolio of
therapeutic and diagnostic products," said Dr. Ledebur. "I am thrilled to
be joining the NanoMed team and to be given the opportunity to bring
NanoMed's products to market while helping to build a sustainable specialty
pharmaceutical company," Ledebur added.

Previously, Dr. Ledebur was Vice President of Research & Development
and Discovery Programs for Caprion Pharmaceuticals Inc., as well as Program
Head of the Antigen Presenting Cell Program at US-based Valentis, Inc.
(formerly GeneMedicine, Inc.). He began his career at Boehringer Ingelheim
Pharmaceuticals Inc. Dr. Ledebur received his Ph.D. in Molecular & Cell
Biology from Pennsylvania State University and his B.Sc. in Biochemistry
from The Ohio State University.

####

About NanoMed Pharmaceuticals, Inc.
NanoMed Pharmaceuticals(R), Inc. ( http://www.nanomedpharm.com ) is an
early-stage specialty pharmaceutical company dedicated to developing
improved therapeutic and diagnostic products to treat or detect cancer and
other serious diseases. The company's lead product is a nanoparticle
formulation of an FDA-approved cancer drug used to treat adults diagnosed
with acute myeloid leukemia. This lead product is being developed using
Nanotemplate Engineering(TM), the company's proprietary nanoparticle
manufacturing technology used to formulate small molecules, peptides,
proteins, plasmid DNA, and diagnostic agents. NanoMed is headquartered in
Kalamazoo, Michigan.

For more information, please click here

Contacts:
Stephen Benoit
President & CEO

NanoMed Pharmaceuticals, Inc.
7107 Elm Valley Drive, Room B1210
Kalamazoo, Michigan 49009 USA
T - (269) 488-8525
F - (269) 488-8544

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Appointments/Promotions/New hires/Resignations/Deaths

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

VDMA photonics steering committee with new members stronger than ever October 14th, 2014

Agar Scientific appoints Paul Balaş as new Technical Sales Manager October 3rd, 2014

PEN Inc. Chairman Scott Rickert Announces Company Vision, Product Priorities and Management Team: Webcast Highlights the Launch of PEN October 3rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE